PIPGEN - PhD Project 14: To screen and analyse the drug-like profile of compounds targeting PI3K.

PIPGEN - PhD Project 14: To screen and analyse the drug-like profile of compounds targeting PI3K.

tres logos kither biotech.PNG

RESEARCH PROFILE: First Stage Researcher (R1[1])

APPLICATION DEADLINE: 27 June 2021

EU RESEARCH FRAMEWORK PROGRAME: HORIZON 2020

MARIE SKOLODOWSKA CURIE GRANT AGREEMENT NUMBER: 955534

[1] First Stage Researcher (R1) PhD candidate or equivalent. Early stage researcher with less than 4 years FTE research experience.

Recuadro con fechas definitivo.png

PhD Project details

 

KITHER has developed two proprietary chemical moieties that modulate PI3K signal transduction events; (1) KIT2012 which has been optimised for inhaled treatment, and (2) KIT2014 has the ability to block PI3Kg scaffolding functions. ESR14 will apply them in Cystic Fibrosis (CF) disease and the severe and lethal Idiopathic Pulmonary Fibrosis (IPF). ESR14 will establish an in vitro cellular model of CF to characterise the role of PI3Kg and of its modulation in the pathogenesis of CF. Immortalised epithelial cells carrying the most prevalent mutation found in CF patients will be used to identify the underlying mechanisms. In parallel, transgenic animals and models of obstructive (CF-like) and restrictive (IPF) airway disease will be generated to characterise the contribution of PI3K in the diverse cell subpopulations (immune cells, epithelial, fibroblasts) that participate in pathogenesis. Secretory mechanisms, ion fluxes, proliferation and membrane dynamics will be assessed.

Host: Kither Biotech (KITHER), Italy.

Supervisor: Prof. Emilio Hirsch.

Doctoral programme: University of Torino (4 years PhD Programme).

Envisioned secondments: University of Cambridge, Josep Carreras Institute.

 

Or, know someone who would be a perfect fit? Let them know!

Teamtailor

Applicant tracking system by Teamtailor